Pharma News

Johnson & Johnson (J&J) has announced a proposed 5.5 billion USD settlement aimed at resolving nearly all remaining U.S. lawsuits alleging that its talc-based products caused ovarian cancer, marking one of the largest mass-tort settlement efforts in the company's history. The proposed agreement covers approximately 76,000 pending claims and will take effect only if at least 95% of eligible claimants agree to participate.

Sandoz, the global leader in affordable medicines, confirms that the Agência Nacional de Vigilância Sanitária (ANVISA) has granted marketing authorisation for Owozy® (semaglutide), which Sandoz will commercialise in Brazil in partnership with Adalvo.

Engineered Gut Bacteria Show Potential as a New Weapon Against Pancreatic CancerResearchers have developed a genetically engineered probiotic bacterium that could offer a promising new approach for treating pancreatic cancer, one of the deadliest forms of cancer with limited therapeutic options. The study demonstrates that a modified strain of Bifidobacterium longum, a naturally occurring gut bacterium, can selectively colonize pancreatic tumors and stimulate a potent anti-tumor immune response.

Akums Drugs & Pharmaceuticals Ltd., India's leading Contract Development and Manufacturing Organization (CDMO), has announced the acquisition of Oriflame India's manufacturing business, marking its entry into the fast-growing color cosmetics manufacturing sector while significantly expanding its personal care and wellness portfolio.

The U.S. Food and Drug Administration (FDA) has approved Tylenol with Naproxen, the first nonprescription fixed-dose combination of acetaminophen and naproxen sodium for up to 12 hours of pain relief. The approval introduces a new over-the-counter (OTC) option for consumers seeking long-lasting, dual-action pain management without a prescription.

Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Susvimo® (ranibizumab) for the treatment of neovascular age-related macular degeneration (nAMD). If the European Commission grants final approval, Susvimo will become the first continuous drug-delivery treatment for nAMD in the European Union.

The U.S. Food and Drug Administration (US FDA) has issued a Warning Letter to Almon Healthcare Private Limited, Ahmedabad, Gujarat, after identifying significant violations of Current Good Manufacturing Practice (CGMP) regulations at its active pharmaceutical ingredient (API) manufacturing facility during an inspection conducted from February 9–13, 2026. The warning letter was issued on July 13, 2026.

Novo Nordisk has announced that it has filed a lawsuit against Eli Lilly and Company in the United States, alleging that Lilly's advertising campaigns for its GLP-1 medicines are misleading and do not present complete scientific information.